Member Info for Globalcrossings

Good Morning... Do a dummy buy... I think this was an over reaction and she'll bounce at some point. It's just that this may be a bit pricey for the smaller PI's...

221-232p :)

http://www.screencast.com/users/globalcrossings/folders/Jing/media/f6b515ac-59cc-4d3d-b313-454de54024bb

GLA!

Excellent entry point and I'm In...:) She's going to Bounce... http://www.screencast.com/users/globalcrossings/folders/Jing/media/c5973fb5-2558-41c5-b15e-5f6468751a26

...

Solid Rns, Small Market Cap & Very few shares on offer... She should move easily in either direction ...:) As Always... DYOR! http://www.screencast.com/users/globalcrossings/folders/Jing/media/9c9df2c9-383e-437c-85e6-0314487703c6 GLA

GLA!

RNS Number : 9877N Medgenics Inc 22 June 2010         Medgenics, Inc. ('Medgenics' or the 'Company')     Higher Dose EPO Biopumps Working in Patients   Misgav, Israel and London, UK -22 June 2010 - Medgenics, Inc. (AIM: MEDG, MEDU), the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, is pleased to announce that the first new patients have now successfully commenced their treatment using biopumps producing middle dose levels of EPO in the Company's ongoing Phase I/II clinical trials with EPODURE. The new patients were also the first to have their Biopumps prepared at a remote site (the GMP processing center in Jerusalem), transported in a sealed chamber and subsequently administered locally at a major teaching hospital in Tel Aviv - thus successfully demonstrating the concept of a regional Biopump processing center serving a local treatment center, which is important for the wider implementation planned in the future.   In the first part of the Company's Phase I/II clinical trial, completed in 2009 at the Hadassah Medical Center in Jerusalem, the equivalent of the lowest recommended dose for EPO (20 IU/kg/day) was prepared at the local GMP center and administered in 6 of the patients treated and one patient was treated with the middle recommended dose (40 IU/kg/day).  The biopumps produced EPO continuously in all the patients, elevating or maintaining the haemoglobin levels in many, even with the lowest EPO dose, with most continuing for the 6 month duration of the trial and one for more than 20 months.    This second part of the trial is being conducted at the Tel Aviv Medical Center, and  is aimed at treating new patients with the medium and higher continuous doses to confirm that haemoglobin will be maintained or elevated over the period of the trial at higher dosage levels of EPO delivery.  Demonstrating elevation of the haemoglobin level and its maintenance within the normal therapeutic range are primary objectives of this trial.   In this new stage of the continuing Phase I/II clinical trial, sufficient EPODURE biopumps will be administered to each patient to provide 40 IU/kg/day.  Two weeks ago, the team conducting the trial at Tel Aviv Medical Center successfully harvested micro-organs from the first two new patients entering the study and processed them to become EPODURE biopumps.  These biopumps produced sufficient EPO per day that only 3 or 4 biopumps were necessary in each patient, and these were administered to them on June 17.   The treatment of these new patients is possible as a result of the recently announced, successful fundraising rounds. The Company is now delivering on its plan to move forward with these trials, which have already demonstrated safety and proof of concept of the EPODURE biopump, and now aim to show a trend of greater h

RNS Number : 9877N Medgenics Inc 22 June 2010         Medgenics, Inc. ('Medgenics' or the 'Company')     Higher Dose EPO Biopumps Working in Patients   Misgav, Israel and London, UK -22 June 2010 - Medgenics, Inc. (AIM: MEDG, MEDU), the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, is pleased to announce that the first new patients have now successfully commenced their treatment using biopumps producing middle dose levels of EPO in the Company's ongoing Phase I/II clinical trials with EPODURE. The new patients were also the first to have their Biopumps prepared at a remote site (the GMP processing center in Jerusalem), transported in a sealed chamber and subsequently administered locally at a major teaching hospital in Tel Aviv - thus successfully demonstrating the concept of a regional Biopump processing center serving a local treatment center, which is important for the wider implementation planned in the future.   In the first part of the Company's Phase I/II clinical trial, completed in 2009 at the Hadassah Medical Center in Jerusalem, the equivalent of the lowest recommended dose for EPO (20 IU/kg/day) was prepared at the local GMP center and administered in 6 of the patients treated and one patient was treated with the middle recommended dose (40 IU/kg/day).  The biopumps produced EPO continuously in all the patients, elevating or maintaining the haemoglobin levels in many, even with the lowest EPO dose, with most continuing for the 6 month duration of the trial and one for more than 20 months.    This second part of the trial is being conducted at the Tel Aviv Medical Center, and  is aimed at treating new patients with the medium and higher continuous doses to confirm that haemoglobin will be maintained or elevated over the period of the trial at higher dosage levels of EPO delivery.  Demonstrating elevation of the haemoglobin level and its maintenance within the normal therapeutic range are primary objectives of this trial.   In this new stage of the continuing Phase I/II clinical trial, sufficient EPODURE biopumps will be administered to each patient to provide 40 IU/kg/day.  Two weeks ago, the team conducting the trial at Tel Aviv Medical Center successfully harvested micro-organs from the first two new patients entering the study and processed them to become EPODURE biopumps.  These biopumps produced sufficient EPO per day that only 3 or 4 biopumps were necessary in each patient, and these were administered to them on June 17.   The treatment of these new patients is possible as a result of the recently announced, successful fundraising rounds. The Company is now delivering on its plan to move forward with these trials, which have already demonstrated safety and proof of concept of the EPODURE biopump, and now aim to show a trend of greater h

RNS Number : 9863N Sinosoft Technology plc 22 June 2010            SINOSOFT TECHNOLOGY PLC ("SINOSOFT" OR "THE COMPANY")   PARTNERSHIP AGREEMENT     Sinosoft, the China-based developer and provider of software and IT solutions to Chinese regional and national government agencies and exporting enterprises, announces the signing of a master strategic partnership agreement with NorthgateArinso UK Limited ("NorthgateArinso"), a global human resources software and services provider.    The agreement will involve Sinosoft collaborating with NorthgateArinsoand Green Oak Solutions Ltd. ("Green Oak"), a partner of NorthgateArinso, to develop carbon management and monitoring products that will be marketed to government and private customers in China.   NorthgateArinso's proprietary software tool, PROIV, will provide a base to build, refine and develop customer service applications. Sinosoft will install hardware and provide the development work to maximise the potential of the PROIV software and Green Oak's Carboncheck software to produce a complete carbon management solution.  In addition, Sinosoft will work with certification companies to verify the data produced from our carbon management solution and thereby potentially enable customers to trade their carbon credits on global exchanges.   Following this partnership agreement, Sinosoft is expected to start bidding for projects at the municipal government level. The collaboration with NorthgateArinsoand Green Oak places the Company in a stronger position to bring in expertise and win contracts.   The carbon emission monitoring market is an area of great potential following support from China's Premier, Wen Jiabao during the 2009 EU-China Summit to address climate change issues. This was reflected in the formation of the National Energy Commission ("NEC") on 27 January 2010 which provides clear guidelines and dates for low carbon and environmental improvement projects. It is possible that following formation of the NEC, formal legislation will soon be passed to impose carbon reduction targets in the private sector. Consequently, carbon emission monitoring mechanism will become essential for regulators and local governments.   Ms Xin, Chief Executive of Sinosoft, commented: "This is an area of significant potential given the keen interest and support shown by the Chinese government to reduce the country's carbon emissions. Being a first mover into this area bodes well for the collaboration and has provided us with the opportunity to start talking to various local governments who are looking to reduce their level of carbon emissions.   "NorthgateArinso was initially introduced to Sinosoft by The China-Britain Business Council and The China Jiangsu Economic and Trade Affairs Office in July 2009 and we have been working on developing this collabo

LONDON (Dow Jones)--Gold and base metals explorer Kryso Resources PLC (KYS.LN) Tuesday said it agreed to enter exclusive talks with a major Chinese mining company about a potential investment. London-based Kryso, which is focused on projects in Tajikistan, said there is no certainty the unnamed Chinese firm will make an investment in Kryso, nor did it give any potential terms. The exclusivity period lasts until Friday. -By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272; jason.douglas@dowjones.com (END) Dow Jones Newswires June 22, 2010 02:25 ET (06:25 GMT)

LONDON (Dow Jones)--Stockbrokers Arden Partners PLC (ARDN.LN) Tuesday reported an "encouraging" first half, with revenue increasing 41% and the pretax loss narrowing slightly, and said it was well placed for growth and profitability from both the U.K. and Indian markets. For the six months ended April 30 Arden posted a pretax loss of GBP240,000 compared with a pretax loss of GBP278,000 in the same period a year earlier. Revenue increased to GBP6.5 million from GBP4.6 million while net assets rose to GBP12.3 million from GBP10.3 million. The company won't be paying an interim dividend. Arden also Tuesday said current Chief Executive Jonathan Keeling will become deputy chairman in due course, focusing on developing the company's Indian franchise. The company said Jeremy Grime has been appointed CEO-designate with immediate effect and will take on the role fully before the end of 2010, subject to regulatory approval. -By Rachael Gormley, Dow Jones Newswires; 44-20-7842-9308; rachael.gormley@dowjones.com (END) Dow Jones Newswires June 22, 2010 02:22 ET (06:22 GMT)

RNS Number : 9830N i-design Group Plc 22 June 2010    IDG 22 June 2010 I-DESIGN GROUP PLC ("i-design" or "the Group")   First Contract in South America   i-design, which has developed and supplies a market leading ATM advertising solution ("atmAd"), enabling ATM network owners to run both third party advertising and their own internal marketing campaigns, is pleased to announce its first contract in the South American marketplace.  The contract, secured via channel partner, Teller Service CIA. LTDA ("Teller"), has been signed with a major bank in Ecuador and is for the deployment of i-design's atmAd solution across the bank's network of approximately 500 ATMs in Ecuador.    Under the terms of the agreement, following the implementation of atmAd, i-design will benefit from an ongoing revenue stream derived from fees relating to the use of its proprietary systems, which facilitate the management of ATM advertising campaigns.  Implementation of atmAd is expected to commence in the coming weeks, with sites expected to go live in the beginning of the fourth quarter of 2010.   The Company views this agreement as a significant strategic gain, establishing atmAd (and the concept of third party advertising on ATMs) in a new territory and helping to open up further opportunities in South America. Importantly, atmAd is a platform independent solution, capable of operating across multiple ATM networks.  Teller also represents the Group in a number of other South American countries.    This new contract follows the announcement issued on 27 May 2010, which reported that the Group had secured its first agreement in the USA, with Cardtronics, Inc, the world's largest non-bank owner of ATMs.    Ana Stewart, CEO of i-design, commented:   "This is a strategically important agreement for us, establishing our ATM advertising solution in a major new marketplace, South America.     We are confident that the benefits of atmAd, which remains globally an unrivalled ATM advertising solution - capable of running on multiple ATM networks - will lead other ATM network owners in South America to explore the opportunity atmAd offers both for market positioning and new revenue generation.      We continue to remain very positive about prospects for expansion both in the UK and internationally."     Enquiries:   i-design group plc Ana Stewart, Chief Executive Ian Sunter, Finance Director T: 01382 541 041   Biddicks Katie Tzouliadis T: 020 7448 1000 Sophie Lane Arbuthnot Securities Tom Griffiths T: 020 7012 2000 Alasdair Younie   About i-design group plc   i-design (AIM: IDG) is the world-leading specialist provider of ATM advertising software and services and developer of atmAd, the only platform independent end-to-end ATM mark

RNS Number : 9557N KDD Group NV 22 June 2010   KDD Group NV 22 June 2010   KDD Group N.V.   ("KDD Group" or the "Group")   Management agreement signed with Swissôtel Hotels and Resorts for the Sky Towers project   KDD Group (AIM: KDDG), the holding company of one of Ukraine's leading real estate investment and development groups, is pleased to announce that it has signed a management agreement with Swissôtel Hotels & Resorts.    The future Swissôtel Kyiv will form part of "Sky Towers", a mixed use development with 513 rooms and suites, 14 serviced residences, a conference center, and numerous recreation facilities.  The Swissôtel Kyiv is anticipated to be open to welcome guests for the 2012 UEFA European Football Championship in June 2012.  This hotel will be the first that Swissôtel has opened in Ukraine.   According to Meinhard Huck, President of Swissôtel Hotels & Resorts, "Swissôtel Kyiv will be another significant step for us in our expansion into Eastern Europe.  Kyiv is home to governmental ministries and authorities, but also to the mechanical engineering, aircraft industries, light and agricultural industries, as well as the state chemical industry. The Ukrainian metropolis is also one of the most important transport nodal points/centres of communication in Eastern Europe - an environment in which superior quality international hotel chains are still in short supply."   Alexander Levin, Chairman of KDD Group, commented: "The board of KDD Group believes that the Kyiv hotel market has significant potential for such high quality projects as Sky Towers and we are very proud to have such a strong and renowned international partner as Swissôtel Hotels & Resorts."   For further information, please visit: http://www.kddgroup.com.ua/ or contact:   KDD Group   Petro Radchuk                                               Tel: +38 050 516 6091   Strand Hanson Limited   Stuart Faulkner / Liam Buswell                        Tel: +44 207409 3494 www.strandhanson.co.uk   Notes to editors:   KDD Group    KDD Group is the holding company of one of Ukraine's leading real estate investment and development groups.  The Company holds a diversified portfolio of real estate projects comprising offices, residential complexes, retail centres and mixed-use projects.  The Company currently has nine projects, of which three are in the construction phase and six are at various stages of design and development.&

Kryso Resources plc ("Kryso" or the "Company") Exclusivity Period Kryso Resources plc advises that it has entered into an exclusivity agreement (the "Agreement") with a major mainland Chinese mining company (the "Potential Investor") to allow exclusive discussions to take place with regard to a potential investment in the Company. The Agreement provides for an exclusivity period until 11:59p.m. BST on Friday, 25 June 2010, during which time Kryso cannot carry on or solicit discussions with any other party in relation to any investment in the Company's shares or the disposal of any of the Company's assets. There can be no guarantee that the Potential Investor will make any investment in the Company, and a further announcement will be made in due course. For further information please contact: Dr. Trevor Davenport/Craig Brown, Kryso Resources plc Tel: +44 (0) 20 7371 0600 Katy Mitchell, WH Ireland Ltd Tel: +44 (0) 161 832 2174 Christian Dennis, Orbis Equity Partners Ltd Tel: +44 (0) 20 3137 1902 vendor

http://www.investegate.co.uk/Article.aspx?id=201006220700109958N

http://www.investegate.co.uk/Article.aspx?id=20100622070100H5979

RNS Number : 9377N NextGen Group PLC 21 June 2010   NextGen Group Plc   ("NextGen" or "the Company")   Result of Annual General Meeting and Director Appointment   NextGen Group plc announces that at the Company's Annual General Meeting, which was held this morning, all the resolutions proposed were duly passed.   Following shareholder approval at the AGM, Mr Barry McAleer has now been appointed as a Director of the Company.   Disclosures under Schedule 2 of the AIM Rules   Barry Edward McAleer, aged 38, has been Head of Sales & Marketing at the Company since 2009 and previously worked for the Company as the science and contract services manager for 6 years until 2007. He is a scientist by training and also has a PhD in Molecular Virology & Protein Expression and an MBA.   There are no other matters which are required to be announced with regard to this appointment under paragraph (g) of Schedule 2 of the AIM Rules.     For further details please contact:   NextGen Group Klaus Rosenau, Chairman +49 160 5516756   Seymour Pierce Jonathan Wright, Nicola Marrin +44 20 7107 8000 This information is provided by RNS The company news service from the London Stock Exchange   END     RAGKFLBLBQFZBBB

Multimedia content and services group UBC Media has signed an agreement with GMG Radio to provide ‘iTunes tagging’ for its 12 radio stations. iTunes tagging allows people listening to the radio to find out which song is being played on the radio and buy it on Apple’s digital music service iTunes. ‘iTunes Tagging is exactly the type of new multimedia development that we want to be involved in,’ said UBC chief executive Simon Cole. ‘It's still at an early stage but should it be widened to the other Apple products, we will be in a very good place to exploit that development.’ GMG’s radio stations include Real Radio and Rock Radio. UBC also announced today that it has sold its 7.5% stake in MXR, the digital radio multiplex company, to GMG Radio’s owner Guardian Media Group, for £136,000.